FDA: Eisai drug increases acidosis risk

The FDA warned doctors that Eisai's epilepsy drug Zonegran can cause a metabolic disorder--acidosis--that can increase the risk of kidney stones and bone disease; the drug's label will be updated accordingly, the agency said. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.